Developer docs
API playgroundTry for free, no card

Search company profiles

Particle3D

Full company profile

uuid0003wou

Namestring
Particle3D
Legal namestring
Ossiform ApS
Websiteurl
particle3d.com
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Particle3D, legally Ossiform ApS (CVR 38838512), is a Danish biomedical company founded in 2017 and headquartered at Oslogade 1, 5000 Odense C, Denmark. It develops 3D-printed bone substitutes based on β-tricalcium phosphate (β-TCP), a resorbable bioceramic that the company shapes via proprietary 3D printing techniques to produce indication-specific, patient-tailored implants. The dual-product portfolio consists of Ossiform Bone — a bio-integrative, structural orthopedic bone graft substitute for clinical reconstruction procedures (orthopedic and spine applications) — and the Ossiform Research Line, which includes P3D Scaffolds and Cell Culture Plates sold to academic and industry researchers in bone tissue engineering and cancer research. The company operates with a small team of 1–10 employees and holds ISO 13485 certification issued by BSI; its clinical products are not yet cleared by regulatory authorities and are not approved for sale, while the technology has been tested in preclinical studies only.

Short descriptiontext

Particle3D (operating as Ossiform ApS) is a Danish biomedical company developing 3D-printed β-tricalcium phosphate bone substitutes and preclinical research scaffolds for orthopedic reconstruction and bone/cancer research applications, currently in preclinical/regulatory stage without approved clinical products.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersOdense, Denmark
HQ citystring
Odense
HQ countrystring
Denmark
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
3D printed bone implants, bioceramic bone grafts, tricalcium phosphate scaffolds, orthopedic bone substitutes, bone tissue engineering
Industry4 codes
PRIMARYHLAHAEAG
Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLAAAGAH
Cartilage, Bone & Musculoskeletal Regeneration
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAAGAB
Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYIMAAAFAI
Medical & Dental Prototyping (Models, Guides, Pre-Op Planning)
Industrials, Manufacturing & Construction/3D Printing/Rapid Prototyping & Product Development (Additive)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Orthopedic, Prosthetic & Surgical Appliances & Supplies3842
Product category
Orthopedic Bone Graft Substitutes
Social media profiles2 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Ossiform Bone Products
TypeHardware Sales
Description

Sale of 3D printed β-TCP bone substitute products for clinical use in bone reconstruction procedures. Currently in preclinical/regulatory approval stage with products not yet cleared for sale.

ossiform.com
2P3D Scaffolds and Research Products
TypeHardware Sales
Description

Sale of P3D Scaffolds and cell culture plates for bone and cancer research applications in preclinical settings

ossiform.com
3Professional Services/Collaboration
TypeProfessional Services
Description

Close collaboration with physicians and industry partners suggests potential for research collaborations and development services

ossiform.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1Ossiform Bone
Description

Bio-integrative and structural orthopedic bone substitutes made from 3D printed β-tricalcium phosphate.

ossiform.com
+3 more records
Core offering1 text field

Particle3D (operating as Ossiform) develops and manufactures 3D-printed bioceramic bone substitutes made from β-tricalcium phosphate (β-TCP). Its commercial offerings include Ossiform Bone, a structural bio-integrative bone graft substitute intended for orthopedic and spine reconstruction, and the Ossiform Research Line comprising P3D Scaffolds and Cell Culture Plates for preclinical bone and cancer research. Clinical products are currently in preclinical / regulatory review and are not yet cleared for sale; research products are sold directly to academic and industry researchers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Potential to reduce need for permanent implant solutions
+2 more records
Product overview1 text field

Ossiform offers a dual-product portfolio centered on 3D printed bone replacement technology. The core commercial offering is Ossiform Bone, which provides bio-integrative and structural orthopedic bone graft substitutes made from 3D printed β-tricalcium phosphate for clinical applications. Complementing this is the Ossiform Research Line, which includes P3D Scaffolds and Cell Culture Plates as specialized research products for bone and cancer studies in preclinical settings. Both product lines utilize the company's proprietary 3D printing technique to create resorbable ceramic bone substitutes.

Product and service4 records
1Ossiform Bone
CategoryOrthopedic Bone Graft Substitutes
Description

Bio-integrative and structural orthopedic bone graft substitute solutions made from 3D printed β-tricalcium phosphate (β-TCP), a resorbable material designed to support bone regeneration with indication-specific biomechanical considerations. Intended for orthopedic and spine surgeons performing bone reconstruction procedures in hospitals and surgical centers.

2Ossiform Research Line
CategoryPreclinical Research Tools
Description

A research product line providing natural bone-like environments for bone tissue engineering in preclinical research, enabling disease mechanism studies and new treatment testing. Served to academic researchers, institutions, and biotech / pharma R&D teams studying bone and cancer.

3P3D Scaffolds
CategoryPreclinical Research Tools
Description

3D printed bioceramic scaffolds made from β-tricalcium phosphate, designed for bone and cancer research applications in preclinical studies. Sold to academic and industry researchers via the company's website.

4Cell Culture Plates
CategoryPreclinical Research Tools
Description

Part of the Ossiform Research Line, providing a 3D printed cell culture system for enhancing bone and cancer research. Sold to academic and industry researchers for preclinical experimentation.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
1Imbros Pty Ltd
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-06-25
Description

Ossiform announced a new distribution partnership with Imbros Pty Ltd covering specified regions. This partnership expands Ossiform's distribution reach for their bone substitute products and P3D Scaffolds through Imbros' established regional distribution network.

ossiform.com
2ABHI 2026 U.S. Accelerator Program
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-02-06
Description

Ossiform was selected for the ABHI 2026 U.S. Accelerator Program, a respected program designed to support medtech companies in entering and expanding in the U.S. market. This accelerator program provides mentorship, networking, and market access support.

ossiform.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Cerapedics markets i-FACTOR, a small peptide (P-15) bone graft for spine and orthopedic fusion. It is comparable as a bone graft substitute company serving the same orthopedic/spine surgeon segment with a biologic alternative to autograft.

TypeEmerging player
Description

Organovo is a bioprinting and tissue engineering company developing 3D-printed human tissue for therapeutic and research applications. It is comparable as a peer using 3D bioprinting approaches to create human tissue constructs, including preclinical disease modeling similar to Particle3D's research line.

TypeEmerging player
Description

Cellink/BICO provides bioprinting hardware, bioinks, and tissue engineering workflows used by researchers building 3D tissue constructs, including bone. It is comparable as a 3D bioprinting platform vendor whose technology stack enables similar research applications as Particle3D's P3D Scaffolds line.

TypeEmerging player
Description

Curasan AG develops, manufactures, and markets synthetic bone regeneration materials for dental, orthopedic, and trauma applications. It is comparable as a European-focused peer in synthetic bone graft substitutes with overlapping indication sets in dental and orthopedic bone repair.

TypeBroad incumbent
Description

Smith+Nephew is a global medical device company with an orthopedics and sports medicine portfolio, including bone graft substitutes and regenerative products for joint reconstruction. It is comparable as a broad incumbent operating in orthopedic reconstruction, the same downstream surgical category that Particle3D targets.

TypeDirect peer
Description

Xtant Medical develops and markets orthobiologic products including bone grafts and spine fixation for orthopedic and neurosurgical applications. It is comparable as a focused bone graft and orthobiologics peer serving clinicians with structural bone replacement solutions.

TypeBroad incumbent
Description

Integra LifeSciences manufactures and markets regenerative tissue technologies and orthopedic implants including bone graft substitutes (e.g., Integra Dermal Regeneration Template and OrthoPediatrics adjacencies). It is comparable as a broad incumbent with overlapping bone graft and orthopedic product lines targeting similar surgical customers.

TypeDirect peer
Description

Biogennix develops and commercializes synthetic bone graft substitutes including calcium phosphate-based bone void fillers for orthopedic and spine fusion. It is directly comparable to Particle3D as a competitor in synthetic, resorbable bone graft substitutes targeting the same clinician customer base.

TypeBroad incumbent
Description

Stryker is a global medical device leader with a large orthopedics and spine franchise including bone substitutes, regenerative materials, and trauma implants. It is comparable as a broad incumbent in the orthopedic and bone graft space with hospital sales reach that could compete or partner with Particle3D.

TypeBroad incumbent
Description

Baxter offers a broad surgical and biosurgery portfolio including bone graft substitutes and regenerative medicine products through Tisseel, Floseal, and other biologics. It is comparable as a large incumbent offering bone graft and related surgical regenerative solutions across hospitals worldwide.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Particle3D

Orthopedic Bone Graft Substitutesparticle3d.com

Particle3D (operating as Ossiform ApS) is a Danish biomedical company developing 3D-printed β-tricalcium phosphate bone substitutes and preclinical research scaffolds for orthopedic reconstruction and bone/cancer research applications, currently in preclinical/regulatory stage without approved clinical products.

What Particle3D does

Particle3D, legally Ossiform ApS (CVR 38838512), is a Danish biomedical company founded in 2017 and headquartered at Oslogade 1, 5000 Odense C, Denmark. It develops 3D-printed bone substitutes based on β-tricalcium phosphate (β-TCP), a resorbable bioceramic that the company shapes via proprietary 3D printing techniques to produce indication-specific, patient-tailored implants. The dual-product portfolio consists of Ossiform Bone — a bio-integrative, structural orthopedic bone graft substitute for clinical reconstruction procedures (orthopedic and spine applications) — and the Ossiform Research Line, which includes P3D Scaffolds and Cell Culture Plates sold to academic and industry researchers in bone tissue engineering and cancer research. The company operates with a small team of 1–10 employees and holds ISO 13485 certification issued by BSI; its clinical products are not yet cleared by regulatory authorities and are not approved for sale, while the technology has been tested in preclinical studies only.

Particle3D firmographics

Firmographics
Name
Particle3D
Legal name
Ossiform ApS
Website
https://particle3d.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Short description
Particle3D (operating as Ossiform ApS) is a Danish biomedical company developing 3D-printed β-tricalcium phosphate bone substitutes and preclinical research scaffolds for orthopedic reconstruction and bone/cancer research applications, currently in preclinical/regulatory stage without approved clinical products.
Ownership category
akta.pro rank

Particle3D industry classification

Industry
Product category
Orthopedic Bone Graft Substitutes
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)
akta.pro industry
PRIMARYHLAHAEAG
Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLAAAGAH
Cartilage, Bone & Musculoskeletal Regeneration
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAAGAB
Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYIMAAAFAI
Medical & Dental Prototyping (Models, Guides, Pre-Op Planning)
Industrials, Manufacturing & Construction/3D Printing/Rapid Prototyping & Product Development (Additive)

Keywords

  • 3D printed bone implants
  • Bioceramic bone grafts
  • Tricalcium phosphate scaffolds
  • Orthopedic bone substitutes
  • Bone tissue engineering

Where Particle3D is headquartered

Location

Headquarters

HQ city
Odense
HQ country
Denmark
HQ region
Europe

Offices1 record

Markets served

Particle3D business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

  1. Ossiform Bone Products: Sale of 3D printed β-TCP bone substitute products for clinical use in bone reconstruction procedures. Currently in preclinical/regulatory approval stage with products not yet cleared for sale.
  2. P3D Scaffolds and Research Products: Sale of P3D Scaffolds and cell culture plates for bone and cancer research applications in preclinical settings
  3. Professional Services/Collaboration: Close collaboration with physicians and industry partners suggests potential for research collaborations and development services

Go-to-market motion3 records

Distribution channels3 records

Marketing channels5 records

Particle3D product offering

Product offering

Core offering

Particle3D (operating as Ossiform) develops and manufactures 3D-printed bioceramic bone substitutes made from β-tricalcium phosphate (β-TCP). Its commercial offerings include Ossiform Bone, a structural bio-integrative bone graft substitute intended for orthopedic and spine reconstruction, and the Ossiform Research Line comprising P3D Scaffolds and Cell Culture Plates for preclinical bone and cancer research. Clinical products are currently in preclinical / regulatory review and are not yet cleared for sale; research products are sold directly to academic and industry researchers.

Product overview

Ossiform offers a dual-product portfolio centered on 3D printed bone replacement technology. The core commercial offering is Ossiform Bone, which provides bio-integrative and structural orthopedic bone graft substitutes made from 3D printed β-tricalcium phosphate for clinical applications. Complementing this is the Ossiform Research Line, which includes P3D Scaffolds and Cell Culture Plates as specialized research products for bone and cancer studies in preclinical settings. Both product lines utilize the company's proprietary 3D printing technique to create resorbable ceramic bone substitutes.

Differentiator

Problem solved

Functional benefit

Brands

  • Ossiform Bone: Bio-integrative and structural orthopedic bone substitutes made from 3D printed β-tricalcium phosphate.
  • Ossiform Research Line
  • P3D Scaffolds
  • We Print Bone

Products and services

  • Ossiform Bone Bio-integrative and structural orthopedic bone graft substitute solutions made from 3D printed β-tricalcium phosphate (β-TCP), a resorbable material designed to support bone regeneration with indication-specific biomechanical considerations. Intended for orthopedic and spine surgeons performing bone reconstruction procedures in hospitals and surgical centers.
  • Ossiform Research Line A research product line providing natural bone-like environments for bone tissue engineering in preclinical research, enabling disease mechanism studies and new treatment testing. Served to academic researchers, institutions, and biotech / pharma R&D teams studying bone and cancer.
  • P3D Scaffolds 3D printed bioceramic scaffolds made from β-tricalcium phosphate, designed for bone and cancer research applications in preclinical studies. Sold to academic and industry researchers via the company's website.
  • Cell Culture Plates Part of the Ossiform Research Line, providing a 3D printed cell culture system for enhancing bone and cancer research. Sold to academic and industry researchers for preclinical experimentation.

Quantifiable outcome

  • Potential to reduce need for permanent implant solutions
  • +2 more outcomes

Companies that use Particle3D

Customer profile

Segments2 records

Ideal customer profiles2 records

Particle3D technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Particle3D partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core and minor.

  • Imbros Pty LtdcoreChannel Partner/ Reseller/ Distributor · 25 June 2026Ossiform announced a new distribution partnership with Imbros Pty Ltd covering specified regions. This partnership expands Ossiform's distribution reach for their bone substitute products and P3D Scaffolds through Imbros' established regional distribution network.
  • ABHI 2026 U.S. Accelerator ProgramminorStrategic or Co-development Partner · 6 February 2026Ossiform was selected for the ABHI 2026 U.S. Accelerator Program, a respected program designed to support medtech companies in entering and expanding in the U.S. market. This accelerator program provides mentorship, networking, and market access support.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

Particle3D competitors and assessment

Company assessment

Direct peers

  • Cerapedics: Cerapedics markets i-FACTOR, a small peptide (P-15) bone graft for spine and orthopedic fusion. It is comparable as a bone graft substitute company serving the same orthopedic/spine surgeon segment with a biologic alternative to autograft.
  • Xtant Medical: Xtant Medical develops and markets orthobiologic products including bone grafts and spine fixation for orthopedic and neurosurgical applications. It is comparable as a focused bone graft and orthobiologics peer serving clinicians with structural bone replacement solutions.
  • Biogennix: Biogennix develops and commercializes synthetic bone graft substitutes including calcium phosphate-based bone void fillers for orthopedic and spine fusion. It is directly comparable to Particle3D as a competitor in synthetic, resorbable bone graft substitutes targeting the same clinician customer base.

Emerging players

  • Organovo: Organovo is a bioprinting and tissue engineering company developing 3D-printed human tissue for therapeutic and research applications. It is comparable as a peer using 3D bioprinting approaches to create human tissue constructs, including preclinical disease modeling similar to Particle3D's research line.
  • Cellink (BICO Group): Cellink/BICO provides bioprinting hardware, bioinks, and tissue engineering workflows used by researchers building 3D tissue constructs, including bone. It is comparable as a 3D bioprinting platform vendor whose technology stack enables similar research applications as Particle3D's P3D Scaffolds line.
  • Curasan AG: Curasan AG develops, manufactures, and markets synthetic bone regeneration materials for dental, orthopedic, and trauma applications. It is comparable as a European-focused peer in synthetic bone graft substitutes with overlapping indication sets in dental and orthopedic bone repair.

Broad incumbents

  • Smith+Nephew: Smith+Nephew is a global medical device company with an orthopedics and sports medicine portfolio, including bone graft substitutes and regenerative products for joint reconstruction. It is comparable as a broad incumbent operating in orthopedic reconstruction, the same downstream surgical category that Particle3D targets.
  • Integra LifeSciences: Integra LifeSciences manufactures and markets regenerative tissue technologies and orthopedic implants including bone graft substitutes (e.g., Integra Dermal Regeneration Template and OrthoPediatrics adjacencies). It is comparable as a broad incumbent with overlapping bone graft and orthopedic product lines targeting similar surgical customers.
  • Stryker: Stryker is a global medical device leader with a large orthopedics and spine franchise including bone substitutes, regenerative materials, and trauma implants. It is comparable as a broad incumbent in the orthopedic and bone graft space with hospital sales reach that could compete or partner with Particle3D.
  • Baxter International (BioSurgery / bone graft portfolio): Baxter offers a broad surgical and biosurgery portfolio including bone graft substitutes and regenerative medicine products through Tisseel, Floseal, and other biologics. It is comparable as a large incumbent offering bone graft and related surgical regenerative solutions across hospitals worldwide.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

Particle3D social profiles

Digital presence

Particle3D compliance and trust

Trust signal

Compliance1 record

Particle3D financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Particle3D leadership team

Management profile

Number of profiles

Profiles6 records

Particle3D funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Particle3D M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Particle3D

What does Particle3D do?

Particle3D (operating as Ossiform) develops and manufactures 3D-printed bioceramic bone substitutes made from β-tricalcium phosphate (β-TCP). Its commercial offerings include Ossiform Bone, a structural bio-integrative bone graft substitute intended for orthopedic and spine reconstruction, and the Ossiform Research Line comprising P3D Scaffolds and Cell Culture Plates for preclinical bone and cancer research. Clinical products are currently in preclinical / regulatory review and are not yet cleared for sale; research products are sold directly to academic and industry researchers.

Is Particle3D a public or private company?

Particle3D is a private company. It is classified as venture growth investor backed and is currently operating.

When was Particle3D founded?

Particle3D was founded in 2017. It employs 11 to 50 people.

Where is Particle3D based?

Particle3D is headquartered in Odense, Denmark, in the Europe region.

How does Particle3D make money?

Three revenue lines are on record. Ossiform Bone Products are the primary driver. The others are P3D Scaffolds and Research Products and professional Services/Collaboration.

Who are Particle3D's main competitors?

Direct peers on record are Cerapedics, Xtant Medical and Biogennix. Emerging players are Organovo, Cellink (BICO Group) and Curasan AG. Broad incumbents are Smith+Nephew, Integra LifeSciences, Stryker and Baxter International (BioSurgery / bone graft portfolio).

Does Particle3D have an API?

No public API is recorded for Particle3D.

What industry is Particle3D in?

Particle3D's product category is Orthopedic Bone Graft Substitutes. Its primary akta.pro industry code is HLAHAEAG, Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM), with a secondary code of HLAAAGAH, Cartilage, Bone & Musculoskeletal Regeneration. Its NAICS code is 541714 and its SIC code is 3842.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals